Analysts at B. Riley started coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a research note issued to investors on Friday. The brokerage set a “neutral” rating and a $35.00 price target on the biopharmaceutical company’s stock. B. Riley’s target price points to a potential downside of 22.07% from the stock’s current price.

Several other equities research analysts have also recently commented on ASMB. Chardan Capital reissued a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. Zacks Investment Research raised Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Jefferies Group assumed coverage on Assembly Biosciences in a report on Wednesday, November 8th. They set a “buy” rating and a $50.00 target price on the stock. BidaskClub cut Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. Finally, ValuEngine cut Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $39.25.

Shares of Assembly Biosciences (NASDAQ ASMB) opened at $44.91 on Friday. The firm has a market capitalization of $920.98, a P/E ratio of -15.12 and a beta of 0.91. Assembly Biosciences has a twelve month low of $12.15 and a twelve month high of $52.37.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $33.70, for a total value of $33,700.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders have sold 4,000 shares of company stock worth $157,660. 19.60% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ASMB. Perceptive Advisors LLC bought a new position in shares of Assembly Biosciences in the fourth quarter valued at $8,679,000. Baker BROS. Advisors LP bought a new position in shares of Assembly Biosciences in the third quarter valued at $1,803,000. State Street Corp bought a new position in shares of Assembly Biosciences in the second quarter valued at $4,234,000. JPMorgan Chase & Co. bought a new position in shares of Assembly Biosciences in the second quarter valued at $3,426,000. Finally, Valeo Financial Advisors LLC purchased a new position in Assembly Biosciences during the 3rd quarter worth approximately $4,963,000. 62.00% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Assembly Biosciences (ASMB) Coverage Initiated at B. Riley” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/05/assembly-biosciences-asmb-coverage-initiated-at-b-riley.html.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.